CD247 and plasma cell myeloma: Early preclinical work demonstrated that a viral construct encoding a second-generation CS1-specific CAR, comprising CD28-CD3ζ intracellular signaling domains, can be expressed in human NK cells to produce CAR-NK effectors with markedly enhanced anti-myeloma activity.